DEXTROSE BP
Sponsors
Astrazeneca AB, AstraZeneca AB
Conditions
Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
Phase 3
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
RecruitingCTIS2023-507689-26-00
Start: 2019-10-07Target: 94Updated: 2025-10-14
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Active, not recruitingCTIS2023-509602-29-00
Start: 2019-02-11Target: 168Updated: 2025-08-21